Evidence map›Paper›PMID 26544706›Full record

ArticleAIDS (London, England)2015

Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy.

Maria Pyra, Renee Heffron, Nelly R Mugo, Kavita Nanda, Katherine K Thomas, Connie Celum, Athena P Kourtis, Edwin Were, Helen Rees, Elizabeth Bukusi and 2 more

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Maria PyraaDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics & Gynaecology, University of Nairobi eSexual, Reproductive, Adolescent and Child Health Research Program, Kenya Medical Research Institute, Nairobi, Kenya fFHI 360, Contraceptive Technology Innovation Department, Durham, North Carolina gDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA hDepartment of Reproductive Health, Moi University, Eldoret, Kenya iWits Reproductive Health and HIV Institute (WRHI), University of the Witwatersrand, Johannesburg, South Africa jCenter for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Renee Heffron
Nelly R Mugo
Kavita Nanda
Katherine K Thomas
Connie Celum
Athena P Kourtis
Edwin Were
Helen Rees
Elizabeth Bukusi
Jared M Baeten
Partners in Prevention HSVHIV Transmission Study and Partners PrEP Study Teams
Kenya Medical Research Institute · KEUniversity of Washington · USFamily Health International 360 · USMoi University · KENational Center for Chronic Disease Prevention and Health Promotion · USUniversity of the Witwatersrand · ZA

Funding

Health Promotion and Disease Prevention Research CenterU48DP005013 · DP · UNIVERSITY OF WASHINGTON · PI HANNON, MARGARET A · 2014 to 2018
$13.3M
Hormonal contraception, pre-exposure prophylaxis, and HIV-1 protectionR21HD074439 · NICHD · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED · 2013 to 2014
$432k
NCCDPHP CDC HHS U48 DP 005013NCCDPHP CDC HHS U48 DP005013NICHD NIH HHS R21 HD074439
6 · The paper itself

Abstract

objectiveThe objective of this study is to assess whether antiretroviral therapy (ART) may diminish the effectiveness of hormonal contraceptive methods.

methodsUsing data from 5153 HIV-infected women followed prospectively for 1-3 years in three HIV prevention studies in Africa, we compared incident pregnancy rates by contraceptive method (implant, injectable, oral or none) and ART use. Multivariable Cox regression models were used to determine adjusted hazard ratios (aHRs) and test interactions between each method and ART use.

resultsDuring follow-up, 9% of women ever used implants, 40% used injectables and 14% used oral contraceptives; 31% of women ever used ART, mostly nevirapine (75% of ART users) or efavirenz-based (15%). Among women not using contraception, pregnancy rates were 13.2 and 22.5 per 100 women-years for those on and not on ART, respectively. Implants greatly reduced the incidence of pregnancy among both women on ART [aHR 0.06, 95% confidence interval (95% CI) 0.01-0.45] and not on ART (aHR 0.05, 95% CI 0.02-0.11). Injectables (aHR 0.18 on ART and aHR 0.20 not on ART) and oral contraceptives (aHR 0.37 on ART and aHR 0.36 not on ART) also reduced pregnancy risk, though by lesser degrees. ART use did not significantly diminish contraceptive effectiveness, although all methods showed nonstatistically significant reduced effectiveness when concurrently using efavirenz.

conclusionHormonal contraceptive methods are highly effective in reducing pregnancy risk in HIV-infected women, including those concurrently using ART. Studies of potential interactions between ART and contraceptives should evaluate real-world effectiveness of contraceptive methods; in this study, implants were the most effective method to prevent pregnancy, even during ART use.

Indexed as

AdolescentAdultAfricaAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveContraceptionContraceptive Agents, FemaleFemaleHIV InfectionsHumansLongitudinal StudiesMaleMiddle AgedPregnancyPregnancy RateProspective StudiesAnti-Retroviral AgentsContraceptive Agents, Female

Identifiers

PMID26544706
PMCPMC4748843
OpenAlexW2281168691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.